Inclusion Criteria:

- ≥ 18 and ≤ 70 years of age

- Histological confirmed advanced or metastatic adenocarcinoma of the stomach

- Have failed for 2 lines of chemotherapy

- Life expectancy of more than 3 months

- ECOG performance scale ≤ 1

- At least one measurable lesion beyond stomach (larger than 10 mm in diameter by
spiral CT scan)

- Duration from the last therapy is more than 6 weeks for nitroso or mitomycin

- More than 4 weeks for operation or radiotherapy

- More than 4 weeks for cytotoxic agents or growth inhibitors

- Adequate hepatic, renal, heart, and hematologic functions (platelets > 80 × 109/L,
neutrophil > 1.5 × 109/L, serum creatinine ≤ 1X upper limit of normal(ULN), bilirubin
< 1.25 ULN, and serum transaminase ≤ 2.5× ULN).

Exclusion Criteria:

- Pregnant or lactating women

- History of other malignancies except cured basal cell carcinoma of skin and carcinoma
in-situ of uterine cervix

- Any factors that influence the usage of oral administration; Evidence of CNS
metastasis

- Intercurrence with one of the following: uncontrolled hypertension, coronary artery
disease, arrhythmia and heart failure

- INR > 1.5 and APPT > 1.5 X ULN

- Abuse of alcohol or drugs

- Certain possibility of gastric or intestine hemorrhage

- Less than 4 weeks from the last clinical trial

- Prior VEGFR inhibitor treatment

- Disability of serious uncontrolled intercurrence infection.